Caribou Biosciences
- Total Funding$159.5 M
OverviewSuggest Edit
Caribou Biosciences is a leading biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins.
Caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. Forbes Magazine has called Cas9 the protein that "could change biotech forever" and the New York Times has noted that "the pace of new discoveries and applications is dizzying." Caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.
| Type | Private | |
| Founded | 2011 | |
| HQ | Berkeley, CA, US | Map |
| Website | cariboubio.com | |
| Employee Ratings |
Recent NewsAll News
- Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
- Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
- Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates
- Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
Key People/Management at Caribou Biosciences
Rachel Haurwitz
Barbara McClung
Steven Kanner
Chris Fuller
Cherry Thomas
Jason O'Byrne
Caribou Biosciences Office Locations
Caribou Biosciences Financials and Metrics
Summary Metrics
Founding Date | 2011 |
Caribou Biosciences total Funding | $159.5 m |
Caribou Biosciences latest funding size | $115 m |
Time since last funding | a year ago |
Caribou Biosciences investors | Maverick Capital, Heritage Group, Novartis, Farallon Capital Management, Invus, Jenny Rooke, Mission Bay Capital, Anterra Capital, Tekla Capital Management, 5 Prime Ventures, F-Prime Capital Partners, Pontifax AgTech, LifeSci Venture Partners, Janus Henderson Investors, Point72, Maverick Ventures, AbbVie Ventures, Ridgeback Capital Investments, Avidity Partners, Monashee Investment Management, Adage Capital Partners, PFM Health Sciences, Avego Bioscience Capital, The Leukemia & Lymphoma Society Therapy Acceleration Program, Heritage Medical Systems, Pontifax Global Food, Agriculture Technology Fund |
Caribou Biosciences Cybersecurity Score
Caribou Biosciences Environment, Social & Governance (ESG) Ratings
Caribou Biosciences Online and Social Media Presence
5.87k Twitter followers
Caribou Biosciences has 5.87k Twitter Followers. The number of followers has increased 1.6% month over month and increased 3.9% quarter over quarter
Caribou Biosciences's Trends
Twitter Engagement Stats for @CaribouBio
249
Tweets
157
Following
5.9k
Followers
11
Tweets last 30 days
10.8
Avg. likes per Tweet
100%
Tweets with engagement
Caribou Biosciences News and Updates
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Caribou Biosciences Frequently Asked Questions
When was Caribou Biosciences founded?
Caribou Biosciences was founded in 2011.
Who are Caribou Biosciences key executives?
Caribou Biosciences's key executives are Rachel Haurwitz, Barbara McClung and Steven Kanner.
How many employees does Caribou Biosciences have?
Caribou Biosciences has 100 employees.
Who are Caribou Biosciences competitors?
Competitors of Caribou Biosciences include Biocytogen, TriArm Therapeutics and Tierra Biosciences.
Where is Caribou Biosciences headquarters?
Caribou Biosciences headquarters is located at 2929 Seventh Street, Berkeley.
Where are Caribou Biosciences offices?
Caribou Biosciences has an office in Berkeley.
How many offices does Caribou Biosciences have?
Caribou Biosciences has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies